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Abstract
Radiation treatment planning plays an important role in modern radiation therapy; it
could simulate to plan the geometric, radiobiological, and dosimetric aspects of the
therapy using radiation transport simulations and optimization. In this chapter, we
have reviewed several quantitative methods used for evaluating radiation treatment
plans and discussed some important considering points. For the purpose of quantita‐
tive plan evaluation, we reviewed dosimetrical indexes like PITV, CI, TCI, HI, MHI,
CN, COSI, and QF. Furthermore, radiobiological indexes like Niemierko’s EUD-based
TCP and NTCP were included for the purpose of radiobiological outcome modeling.
Additionally, we have reviewed dose tolerance for critical organs including RTOG
clinical trial results, QUENTEC data, Emami data, and Milano clinical trial results. For
the purpose of clinical evaluation of radiation-induced organ toxicity, we have re‐
viewed RTOG and EORTC toxicity criteria. Several programs could help for the easy
calculation and analysis of dosimetrical plan indexes and biological results. We have
reviewed the recent trend in this field and proposed further clinical use of such pro‐
grams. Along this line, we have proposed clinically optimized plan comparison proto‐
cols and indicated further directions of such studies.
Keywords: Treatment plan evaluation, Dosimetrical indices, Radiobiological indices,
Tolerance doses, Radiation toxicity
1. Introduction
We have reviewed the methods used for quantitative comparison of different radiation
treatment plans, the process of treatment plan comparison protocol, and the further direction
of treatment plan evaluation programs. For the purpose of quantitative plan evaluation, we
reviewed dosimetrical indexes like prescription isodose to target volume (PITV) ratio,
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homogeneity index (HI), conformity index (CI), target coverage index (TCI), modified dose
homogeneity index (MHI), conformity number (CN), critical organ scoring index (COSI), and
quality factor (QF). Furthermore, radiobiological indexes like Niemierko’s EUD-based tumor
control probability (TCP) and normal tissue complication probability (NTCP) were included
for the purpose of radiobiological outcome modeling. Additionally, we have reviewed dose
tolerance for critical organs including RTOG clinical trial results, QUENTEC data, Emami data,
and Milano clinical trial results. For the purpose of clinical evaluation of radiation-induced
organ toxicity, we have reviewed RTOG and EORTC toxicity criteria. Several programs could
help for the easy calculation and analysis of dosimetrical plan indexes and biological results.
We have reviewed the recent trend in this field and proposed further clinical use of such
programs. It is well known that plan comparison study still remain many controversies. The
major issue is that plan evaluation methods are used in plan comparison and plan optimiza‐
tion. We have reviewed well-known dosimetric and biological plan indexes and several
commercial and non-commercial plan evaluation programs. Along this line, we have proposed
clinically optimized plan comparison protocols and indicated the further directions of such
studies.
2. Background: Radiotherapy, radiation treatment planning, and planning
decision support program
2.1. Radiotherapy
Over the past few decades, radiation treatment has become a technologically advanced field
in modern medicine, especially with the advent of intensity-modulated radiation therapy
(IMRT) [1]. Traditional radiation therapy planning is a manual, iterative, and simple process
in which treatment fields are placed and beam modifiers are inserted.
Modifications are then made after manual inspection of the dose distribution calculated after
each iteration [2]. In IMRT, the dose calculation engine specified dose distribution over the
target volume and surrounding normal structures. Furthermore, dose calculation engine
displayed a 2D dose intensity map by using its optimization algorithms [3]. Moreover, the
inverse planning algorithm required users to set a dose/volume criteria for the specific organ/
structure, and the computer calculated to find out a final solution to satisfy the criteria. [4].
Another breakthrough of modern radiation treatment is image-guided radiotherapy (IGRT).
With the adoption and integration of imaging information in treatment designs, IGRT is the
most innovative area in advanced radiotherapy [5]. IGRT has increased knowledge of exact
tumor targets and their movements during the treatment process [6]. Despite improvements
in target coverage and normal tissue sparing, the implementation of IMRT and IGRT remains
a labor-intensive trial and error process. The creation of optimized treatment plans for
personalized therapy still requires significant time and effort. Radiation treatment includes
CT simulation, organ contouring, treatment planning, quality assurance, and dose delivery
(Figure 1) [7].
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Figure 1. Clinical workflow of radiation treatment plan (a); radiation treatment includes CT simulation, organ contour‐
ing, treatment planning, quality assurance, and dose delivery. (b); configuration of radiotherapy equipment.
2.2. Radiation treatment planning
For radiation treatment, a team of radiation oncologists, radiation therapists, medical physi‐
cists, and medical dosimetrists plan the appropriate external beam radiotherapy treatment
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technique for a patient with cancer [8]. There are generally two different types of planning
algorithms, forward planning and inverse planning. The forward planning technique is mostly
used in external-beam radiotherapy treatment planning process. For example, a medical
physicist determines the beam angles in the treatment planning systems to maximize tumor
dose when sparing the healthy tissues. This type of planning is used for the majority of
external-beam radiotherapy treatments, but is only useful for relatively uncomplicated cases
in which the tumor has a simple shape and is not near any critical organs. Inverse planning is
a technique used to inversely design radiotherapy treatment plans (Figure 2). The radiation
oncologist defines a patient’s critical organs and tumor. Then, the dosimetrist provides target
doses for each. An optimization program is then run to find the treatment plan that best
matches all input criteria. This type of trial-and-error planning process is time and labor
intensive.
Figure 2. Workflow of inverse radiation treatment planning.
There are several commercial treatment planning systems (TPS) available nowadays. Table 1
summarizes information about commercial TPS [9].
2.3. Planning decision support program
Dose volume histogram (DVH) provides dose volume coverage information. However, it fails
to provide more information like hot spot and dose homogeneity. Dosimetrical indices were
widely used for plan evaluation for a specific purpose. For example, a homogeneity index
refers to the intensity of dose distributions in target volume, those plans with both “hot” spot
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and “cold” spot could be distinguished by this index. Additionally, some indices consider dose
conformity in the target volume. Conformity index was an example of such indices. Another
method to review and evaluate treatment plan quality was biological index. A tumor control
probability could indirectly estimate a tumor could be controlled by a certain dose. Further‐
more, normal tissue complication probability could estimate the probability of a surrounding
critical structure becomes some radiation-induced complications. Many programs have been
designed and developed to calculate both dosimetrical and biological indices since the 2000s
[10-29]. This is shown in Figure 3.
Treatment planning system Company Website
ScandiPlan Scanditronix http://www.scanditronix-magnet.se
Pinnacle3 Philips Healthcare http://www.healthcare.philips.com
ISOgray DOSIsoft http://www.dosisoft.com
iPlan Brainlab https://www.brainlab.com
XiO Electa http://www.elekta.com
Monaco Electa http://www.elekta.com
Theraplan Plus Electa http://www.elekta.com
Oncentra MasterPlan Electa http://www.elekta.com
Oncentra Prostate Electa http://www.elekta.com
Oncentra GYN Electa http://www.elekta.com
Pinnacle Philips Healthcare http://www.healthcare.philips.com
Plato RTS Electa http://www.elekta.com
Plato BPS Electa http://www.elekta.com
Cad Plan Varian Medical Systems http://www.varian.com
Corvus nomos http://www.nomos.com
KL-Medical Electron Linear
Accelerator treatment system
KLZ Healthcare http://klz.comedb.com
Prowess 3-D Prowess http://www.prowess.com/
Brachyvision Varian http://www.varian.com
Leksell GammaPlan® Electa http://www.elekta.com
Eclipse Varian Medical Systems http://www.varian.com
VariSeed Varian Medical Systems http://www.varian.com
RayStation RaySearch Laboratories http://www.raysearchlabs.com
Table 1. Commercial RTP lists
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Figure 3. Timeline of plan analysis programs [10-11, 13, 17-18, 22-24, 28, 52-53].
3. Plan evaluation
3.1. Plan evaluation methods
3.1.1. Qualitative analysis
In conventional radiation therapy, an isodose distribution is used for plan analysis and
evaluation. Figure 4 shows the typical isodose distribution of 3D conformal treatment plans
and IMRT plans.
3.1.2. Quantitative analysis
DVH is the relationship between the dose distribution of a certain organ and 100% normalized
volume of such organ. It was calculated and generated based on 3D reconstructed images in
the treatment planning systems [9]. DVH could simplify 3D information of dose distribution
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into a 2D graph or quantitative values [30-34]. Figure 5 shows a typical DVH for helical
tomotherapy (HT) and intensity modulated proton therapy (IMPT) plans for prostate cancer.
Figure 5. Typical DVH for helical tomotherapy (HT) treatment plan and intensity modulated arc therapy (IMAT) plan
of prostate cancer: (a) axial slice, (b) sagittal slice. Planning target volume (PTV), critical structures, and four different
isodose lines shown. (c) Dose-volume histogram comparison for prostate case. Solid lines, tomotherapy plan; dashed
lines, intensity modulated arc therapy (IMAT) plan (International Journal of Radiation Oncology Biology Physics,
69(1), 2007).
Figure 4. Typical isodose distribution of (a) 3D conformal treatment plan and (b) IMRT plan.
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4. Plan analysis
Isodose distribution and DVH analysis were insufficient compared to complicated and
advanced planning techniques. As the femoral head DVHs in Figure 4 show, it was difficult
to distinguish whether IMPT (continuous red line) or HT (dashed red line) plans were superior.
For low dose volume (V0 to V20), IMPT was more favorable than HT. However, this relationship
reversed for high dose volume (V20 to V50). As a result, there are several indexes that may
represent target conformity and dose homogeneity [31, 35-38].
4.1. Dosimetrical analysis
4.1.1. Index
Several quantitative evaluation tools were reviewed in this paper. These included the pre‐
scription isodose to target volume (PITV) ratio, homogeneity index (HI), conformity index (CI),
target coverage index (TCI), modified dose homogeneity index (MHI), conformity number
(CN), quality factor (QF) for PTV, maximum dose, mean dose, dose volume histogram (DVH),
and critical organ scoring index (COSI) for the OAR (Figure 6).
4.1.2. PTV index
The PITV ratio, obtained by dividing prescription isodose surface volume by target volume,
is expressed as:
= PIVPITV TV (1)
In the above equation, PIV represents prescription isodose surface volume and TV refers to
target volume [39]. The PITV ratio is a conformity measure, and a value of 1.0 indicates that
the volume of the prescription isodose surface equals that of the PTV. A PITV ratio of 1.0 does
not necessarily imply that both volumes are similar. To ensure adequate PTV coverage, this
measure should always be used in conjunction with a PTV-DVH [39]. The CI and HI indices
for targets were computed to assess the quality of IMRT plans. CI is defined as the ratio of
target volume and the volume inside the isodose surface that corresponds to the prescription
dose. CI is generally used to indicate the portion of a prescription dose that is delivered inside
the PTV [40].
CI is expressed as:
= PDPTVCI PIV (2)
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In the above equation, PIV represents prescription isodose surface volume and PTVPD
represents PTV coverage at the prescription dose. CI of 1 indicates that 100% of a prescription
dose is delivered to the PTV, and no dose is delivered to any adjacent tissue [40]. The CI is less
than 1 for most clinical cases. Higher CI values indicate poorer dose conformity to the PTV.
HI is defined as the ratio of maximum dose delivered to the PTV divided by the prescription
dose delivered to the PTV [41].
HI is expressed as:
max= DHI PD (3)
In the above equation, Dmax represents PTV maximum dose. An HI of 1 represents the ideal
uniform dose within a target. Higher HI values indicate greater dose heterogeneity in the PTV
[39].
TCI refers to the exact coverage of PTV in a treatment plan for a given prescription dose.
TCI is expressed as:
= PDPTVTCI PTV (4)
In the above equation, PTVPD represents PTV coverage at the prescription dose.
MHI is similar to HI, and is expressed as [41]:
95
5
= DMHI D (5)
In the above equation, D95 and D5 represent doses received at 95% and 5% of the volume
coverage, respectively.
Conformity number (CN) is a relative measurement of dosimetric target coverage and sparing
of normal tissues in a treatment plan [42]. The CN is expressed as:
= ´ = ´PD PDPTV PTVCN TCI CI PTV PIV (6)
In the above equation, PTVPD refers to PTV coverage at the prescription dose and PIV repre‐
sents prescription isodose surface volume [42].
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Figure 6. Comparison of the various dosimetrical indices in various clinical cases.
Evolution of Ionizing Radiation Research118
4.2 Biological analysis
4.2.1. Overview of biological models
For radiobiological model-based plan evaluation, Niemierko’s equivalent uniform dose
(EUD)-based NTCP and TCP model were reviewed [12, 19]. First, the DVHs from each plan
were exported from the appropriate treatment planning system (TPS) for each modality. The
DVHs were then imported into MATLAB version R2012a (The Math Works, Inc., Natick, MA,
USA) for TCP and NTCP modeling analysis. According to Neimierko’s phenomenological
model, EUD is defined as:
( )
1
1=
é ù= ê úë ûå
aa
i i
i
EUD V EQD (7)
where a is a unitless model parameter that is specific to the nominal tumor structure of interest,
and Vi is a unitless parameter that represents the ith partial volume receiving dose Di in Gy [12].
Since the relative volume of the whole structure of interest corresponds to 1, the sum of all
partial volumes Vi will equal 1. In equation [5], the EQD is a biologically equivalent physical
dose of 2 Gy defined as:
2
a
b
a
b
æ öç ÷+ç ÷è ø= ´ æ ö+ç ÷è ø
f
D
nEQD D (8)
where nf and df =D/nf are the number of fractions and the dose per fraction size of the treatment
course, respectively. In this equation, α/β is the tissue-specific linear quadratic (LQ) parameter
of the organ being exposed. Niemierko’s TCP [12] is defined as:
50
50
1
1
g= æ ö+ ç ÷è ø
TCP
TCD
EUD
(9)
where TCD50 is the tumor dose required to control 50% of cancer cells when a tumor is
homogeneously irradiated and γ50 is a unitless model parameter that is specific to the tumor
of interest. The slope of the dose response curve is described by γ50. Niemierko’s NTCP [19] is
defined as:
50
50
1
1
g= æ ö+ ç ÷è ø
TCP
TCD
EUD
(10)
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where TD50 is the tolerance dose of a 50% complication rate at a specific time (e.g. 5 years in
the Emami et al. normal tissue tolerance data [43]) for an entire organ of interest. This parameter
also describes the slope of the dose response curve.
4.3. Overall plan index
4.3.1. Overall plan index
A comprehensive quality index (CQI) including surrounding OARs were introduced to
evaluate the individual difference between OARs and PTV and the small volume of critical
structures. CQI is expressed as [44]:
( )
( )
1
max
21 1 max
1 1
= =
= =å å
planN N
i plani i
DCQI QIN N D (11)
In this equation, I is the index of the critical organs, which are several critical structures in
certain plan. CQI was designed to compare the ability of avoiding these organs around the
PTV given the same weighting to all organs. Although CQI may overweight certain organs
that are below tolerance, we chose this index as it represents a global measure of the capability
of avoiding sensitive structures. Individual Qis are shown for direct comparison of each OAR.
A CQI less than one indicates that HT provides a better plan for the surrounding OARs, and
vice versa.
4.3.2. COSI
The COSI index accounts for both target coverage and critical organ irradiation [45]. The main
advantage of this index is its ability to distinguish between different critical organs. COSI is
expressed as:
( )
1
1 >= -ån i toli V OARCOSI w TCI (12)
where Vi(OAR)>tol is the volume fraction of OAR that receives more than a predefined tolerance
dose. TCV is the volumetric target coverage, which is defined as the fractional volume of PTV
covered by the prescribed isodose. Modified COSI is expressed as:
10 20 80
1 8=
æ ö+ + += ç ÷è øå
L
i
i
COSI COSI COSImCOSI W (13)
Although the COSI index focuses only on OARs that receive high dose region volumes, the
modified COSI considers both high dose and low dose regions.
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4.3.3. Quality factor
The quality factor (QF) introduced in this study is a dosimetrical index that can evaluate the
quality of an entire plan [23]. The QF of a plan is analytically expressed as:
1
2.718exp
=
é ùæ ö= -ê úç ÷è øë ûå
N
i i
i
QF W X (14)
In the above equation, Xi represents all PTV indices, including PITV, CI, HI, TCI, MHI, CN,
and COSI. The weighting factor (Wi) values can be adjusted between 0 and 1 for all relatively
weighted indices for a user-defined number of indices (N). A weighting factor of 1 was used
for all separate indices. Thus, the QF was mainly used to compare the conformity of plans
throughout various trials of a treatment.
5. Radiation tolerance dose and toxicity
The dose to critical structures plays an important role in treatment plan evaluation and is a
challenging parameter in radiotherapy treatment planning. Here, Emami data [43], QUENTEC
data [46], RTOG data, and the Milano study were reviewed. Doses based on tumor location in
the body related to critical organs are as follows (Table 2-4).
5.1. Radiation toxicities
The assessment and reporting of toxicity plays a central role in oncology [47-50]. The founda‐
tion of toxicity reporting is the toxicity criteria system. Multiple systems have been developed
in the last 30 years, and they have evolved substantially since their first introduction. The wide
adoption of standardized criteria will facilitate comparison between institutions and clinical
trials.
The Radiation Therapy Oncology Group (RTOG) acute radiation morbidity scoring criteria
developed in 1984 consists of 13 scales that cover most body regions [51]. This system was used
by the RTOG and in other clinical trials for over 30 years. The inclusion of acute radiation
criteria into a multimodality grading system facilitated toxicity grading in all oncologic
disciplines. This system also allows radiation oncologists to recognize and grade toxicities that
were not available in the previous RTOG system. Tables 5 and 6 summarize acute toxicity
categorized by body region.
The RTOG/EORTC (European Organization for Research and Treatment of Cancer) system for
scoring late effects was developed in 1984 alongside the RTOG acute criteria. It contains 16
organ categories (Tables 7, 8) and has been used widely. However, its shortcomings have
prompted the development of other systems.
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RTOG data QUANTEC data Emami Data Milano Data 
Critical 
Structure 
Dose/ 
fx 
Vol. Dose 
Max. 
Dose 
Protocol Treated organ 
Critical 
Structure 
Vol. 
Dose/
Vol. 
Max. 
Dose 
Toxicity 
Rate 
Toxicity 
Endpoint 
Organ TD 5/5     TD 50/5     Organ
Dose 
tolerance
Endpoint
Brachial 
Plexus 
2 Gy 5% 60 Gy   619 Postop H&N 
Brain 
    <60 Gy <3% 
Symptomatic 
necrosis 
  Whole  2/3  1/3 Whole  2/3  1/3       
2 Gy     60 Gy 522 Definitive H&N     72 Gy 5% 
Symptomatic 
necrosis 
Brain 4500 5000 6000 6000 6500 7500       
2 Gy     66 Gy 
0619, 061
7 
Postop H&N,  
lung, 
nasopharynx 
    90 Gy 10% 
Symptomatic 
necrosis 
                    
3 Gy     36 Gy 937 Lung             
Brachial 
plexus 
6000 6100 6200 7500 7600 7700       
4 Gy     30 Gy 937 Lung                                 
Brainstem 
1.8-2Gy  0.03cc   
55 Gy 
(0.03 
cc) 
539 
Intermediate 
risk 
meningioma 
Brain stem
    <54 Gy <5% 
Neuropathy 
or necrosis 
Brain 
stem 
5000 5300 6000 6500 – – 
Brain
stem 
V60 < 0.9 
mL 
<5% 
grade >= 
1 toxicity
33 fxs     54 Gy 615 Nasopharynx 
D1-10 
cc 
<= 59 
Gy 
  <5% 
Neuropathy 
or necrosis 
                    
1.8-2Gy     
60 Gy 
(0.03 
cc) 
0539, 082
5 
High risk 
meningioma, 
glioblastoma 
    <64 Gy <5% 
Neuropathy 
or necrosis 
                    
2 Gy     
52 Gy 
(0.03 cc 
1016 Oropharynx                                 
Cochlea 33 fxs 5% 55 Gy   615 Nasopharynx Cochlea Mean
<=45 
Gy 
  <30% 
Sensory-
neural 
hearing loss
Ear 5500 5500 5500 6500 6500 6500       
Larynx, 
glottis 
Mean 20 Gy     1016 Oropharynx 
Larynx 
    <66 Gy <20% 
Vocal 
dysfunction
Larynx 
(necrosis
) 
7000 7000 7900 8000 8000 9000       
2 Gy     45 Gy 
0619, 061
5 
Postop H&N, 
definitive H&N, 
nasopharynx 
Mean <50 Gy   <30% Aspiration 
Larynx 
(edema) 
4500 4500 – 8000 – –       
              Mean <44 Gy   <20% Edema                     
              V50 <27%   <20% Edema                     
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 RTOG data QUANTEC data Emami Data Milano Data 
Critical 
Structure 
Dose/ 
fx 
Vol. Dose 
Max. 
Dose 
Protocol Treated organ 
Critical 
Structure 
Vol. 
Dose/
Vol. 
Max. 
Dose 
Toxicity 
Rate 
Toxicity 
Endpoint 
Organ TD 5/5     TD 50/5     Organ
Dose 
tolerance
Endpoint
Lens 
1.8-2Gy     
5 Gy 
(0.03 
cc) 
539 
Intermediate 
risk 
meningioma 
            Lens 1000 – – 1800 – –       
1.8-2Gy     
7 Gy 
(0.03 
cc) 
0539,  
0825 
High risk 
meningioma, 
glioblastoma 
                                
33 fxs     25 Gy 615 Nasopharynx                                 
Lips 2 Gy Mean 
<20 
Gy 
  1016 Oropharynx                                 
Mandible/ 
TM joint 
2 Gy     66 Gy 1016 Oropharynx                                 
33 fxs 1 cc 75 Gy   615 Nasopharynx             
TMJ 
mandi-
ble 
6000 6000 6500 7200 7200 7700       
33 fxs     50 Gy 615 Nasopharynx                                 
Optic 
chiasm 
33 fxs     50 Gy 615 Nasopharynx 
Optic 
nerve/ 
chiasm 
    <55 Gy <3% 
Optic 
neuropathy
Optic 
chiasm 
5000 – – 6500 – –       
1.8-2 Gy     
54 Gy 
(0.03 
cc) 
539 
Intermediate 
risk 
meningioma 
    55-60 Gy 3-7% 
Optic 
neuropathy
                    
1.8-2 Gy     
56 Gy 
(0.03 
cc) 
0539,  
0825 
High risk 
meningioma, 
glioblastoma 
    >60 Gy >7-20% 
Optic 
neuropathy
                    
Optic 
nerve 
1.8-2 Gy     
50 Gy 
(0.03 
cc) 
0539,  
0615 
Intermediate 
risk 
meningioma, 
nasopharynx 
                                
1.8-2 Gy     
55 Gy 
(0.03 
cc) 
0539,  
0825 
High risk 
meningioma, 
glioblastoma 
            
Optic 
nerve 
5000 – – 6500 – –       
Oral 
cavity 
33 fxs Mean <40 Gy   615 Nasopharynx                                 
Oral 
cavity 
(non-
involved) 
2 Gy Mean <30 Gy 60 Gy 1016 Oropharynx                                 
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 RTOG data QUANTEC data Emami Data Milano Data 
Critical 
Structure 
Dose/ 
fx 
Vol. Dose 
Max. 
Dose 
Protocol Treated organ 
Critical 
Structure 
Vol. 
Dose/
Vol. 
Max. 
Dose 
Toxicity 
Rate 
Toxicity 
Endpoint 
Organ TD 5/5     TD 50/5     Organ 
Dose 
tolerance
Endpoint
Parotid 
Glands 
2 Gy 
Mean 
one 
gland 
<26 Gy   
0619,  
0522, 
1016 
Postop H&N, 
definitive H&N, 
oropharynx 
Parotid, 
bilateral 
Mean
<=25 
Gy 
  <20% 
Long-term 
salivary 
function 
<25% 
                    
2 Gy 
V50 
one 
gland 
<30 Gy   
0619, 
0522 
Postop H&N, 
definitive H&N 
Mean
<=39 
Gy 
  <50% 
Long-term 
salivary 
function 
<25% 
Parotid 
gland 
3200 3200 – 4600 4600   Parotid
Mean 
dose < 
26 Gy 
Late 
grade 2 
xerostom
ia, >75% 
function
al loss 
2 Gy 
Combi
ned 20 
cc 
<20 Gy   
0619, 
0522 
Postop H&N, 
definitive H&N 
Parotid, 
unilateral
Mean
<=20 
Gy 
  <20% 
Long-term 
salivary 
function 
<25% 
                    
Pharynx, 
postcricoid 
33 fxs     45 Gy 615 Nasopharynx                                 
Pharynx, 
posterior 
wall 
2 Gy 33% 50Gy   1016 Oropharynx 
Pharyngeal 
constrictors
Mean
<=50 
Gy 
  <20% 
Symptomatic 
dysphagia 
and 
aspiration 
                    
2 Gy 15% 60Gy   1016 Oropharynx                                 
2 Gy Mean 45Gy   1016 Oropharynx                                 
Retina 
1.8-2 Gy     
45 Gy 
(0.03 
cc) 
539 
Intermediate 
risk 
meningioma 
                                
1.8-2 Gy     
50 Gy 
(0.03 
cc) 
0539,  
0825, 
0615 
High risk 
meningioma, 
glioblastoma, 
nasopharynx 
            Retina 4500 – – 6500 – –       
Spinal 
Cord 
1.8 Gy     45 Gy 
0623, 
0615 
Lung, 
Nasopharynx 
Spinal cord
    50 Gy 0.20% Myelopathy
Spinal 
cord 
(20cm) (10cm) (5 cm)
– 
(10cm) (5 cm)
Spinal 
cord 
Max < 50 
Gy 
<5% 
grade >= 
3 toxicity
  2 Gy     
48 Gy 
(0.03 
cc) 
0619, 
0522 
Postop H&N, 
definitive H&N 
    60 Gy 6% Myelopathy 4700 5000 5000 7000 7000
Cervical 
spinal 
cord 
EUD < 
52 Gy, 
Max < 55
Gy 
<5% 
grade >= 
3 toxicity
Submandi
bular 
Gland 
2 Gy Mean <39 Gy   1016 Oropharynx     69 Gy 50% Myelopathy                     
 
Table 2. Radiation tolerance dose in head and neck
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 RTOG data QUANTEC data Emami Data Milano Data
Critical 
Structure 
Dose/ 
fx 
Vol. Dose 
Max. 
Dose 
Protocol Treated organ 
Critical 
Structure 
Vol. Dose/Vol.
Max. 
Dose 
Toxicity 
Rate 
Toxicity 
Endpoint 
Organ TD 5/5     TD 50/5     Organ 
Dose 
tolerance
Endpoint
Esopha-
gus 
1.8 Gy Mean 34 Gy   
0623,  
0617 
Lung 
Esophagus
Mean <34 Gy   5-20% 
Grade 3+ 
esophagitis 
  Whole  2/3  1/3 Whole  2/3  1/3 
Esopha-
gus 
V50 and 
S50 < 30%
5% risk of 
late 
toxicity 
1.8 Gy 10 cm 60 Gy   623 Lung V35 <50%   <30% 
Grade 2+ 
esophagitis 
Esophagus 
5500 5800 6000 6800 7000 7200
      
2 Gy Mean 30 Gy   1016 Oropharynx V50 <40%   <30% 
Grade 2+ 
esophagitis 
(stricture, 
perforation) 
      
3 Gy     47 Gy 937 Lung V70 <20%   <30% 
Grade 2+ 
esophagitis 
Thyroid 4500     8000           
Heart 
1.8 Gy 33% 60 Gy   
0623,  
0617 
Lung 
Heart 
,Pericardiu
m 
Mean <26 Gy   <15% Pericarditis Heart 
4000 4500 6000 5000 5500 7000
Heart 
V33 < 
60% 
5% excess 
cardiac 
mortality
1.8 Gy 33% 50 Gy   436 Esophagus V30 <46%   <15% Pericarditis (pericarditis) 
V38 < 
33% 
1.8 Gy 67% 45 Gy   
0623, 0617
 0436 
Lung, 
esophagus 
Heart V25 <10%   <1% 
Long term 
cardiac 
mortality 
              
V42 < 
20% 
1.8 Gy 100% 40 Gy   
0623, 0617
 0436 
Lung, 
esophagus 
                                
3 Gy     47 Gy 937 Lung                                 
3 Gy V45 <30%   937 Lung                                 
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RTOG data QUANTEC data Emami Data Milano Data
Critical 
Structure 
Dose/ 
fx 
Vol. Dose 
Max. 
Dose 
Protocol Treated organ 
Critical 
Structure 
Vol. Dose/Vol.
Max. 
Dose 
Toxicity 
Rate 
Toxicity 
Endpoint 
Organ TD 5/5     TD 50/5     Organ 
Dose 
tolerance
Endpoint
Lung, 
single 
2 Gy 
3 cm 
CW to 
field 
    413 Breast 
Lung 
V20 <=30%   <20% 
Symptomatic 
pneumonitis
Lung 1750 3000 4500 2450 4000 6500
Lung 
V13 < 
40% 
Late 
grade 2 in 
<10-20%
Lungs, 
total 
2 Gy V20 20%   630 Sarcoma Mean 7 Gy   5% 
Symptomatic 
pneumonitis
Rib cage – – 5000 – – 6500
V20 < 25-
30% 
Late 
grade 3 in 
<5-10% 
2 Gy V20 37%   0617, 0623 Lung Mean 13 Gy   10% 
Symptomatic 
pneumonitis
              
V30 < 10-
15% 
  
2 Gy Mean 20 Gy   617 Lung Mean 20 Gy   20% 
Symptomatic 
pneumonitis
              
MLD < 
10-20 Gy
  
3 Gy Mean 20 Gy   937 Lung Mean 24 Gy   30% 
Symptomatic 
pneumonitis
                    
3 Gy V20 <= 30%   937 Lung Mean 27 Gy   40% 
Symptomatic 
pneumonitis
                    
Small 
Bowel 
3 Gy 150 cc 30 Gy   937 Lung 
Small bowel 
(individual 
loops) 
V15 <120 cc   <10% 
Grade 3+ 
toxicity 
Small 
intestine 
4000 – 5000 5500 – 6000
      
3 Gy 100 cc 35 Gy   937 Lung 
Small bowel 
(peritoneal 
cavity) 
V45 <195 cc   <10% 
Grade 3+ 
toxicity 
(obstruction, 
perforation) 
      
3 Gy 50 cc 40 Gy   937 Lung                                 
3 Gy 1 cc 45 Gy   937 Lung                                 
4 Gy 100 cc 30 Gy   937 Lung                                 
4 Gy 50 cc 35 Gy   937 Lung             Stomach 
5000 5500 6000 6500 6700 7000
      
4 Gy 1 cc 40 Gy   937 Lung Stomach D100 <45 Gy   <7% Ulceration 
(ulceration,p
erforation) 
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RTOG data QUANTEC data Emami Data Milano Data
Critical 
Structure 
Dose/ 
fx 
Vol. Dose 
Max. 
Dose 
Protocol Treated organ 
Critical 
Structure 
Vol. Dose/Vol.
Max. 
Dose 
Toxicity 
Rate 
Toxicity 
Endpoint 
Organ TD 5/5     TD 50/5     Organ 
Dose 
tolerance
Endpoint
Spinal 
Cord 
1.8 Gy     45 Gy 0623, 0615 
Lung, 
Nasopharynx 
Spinal cord
    50 Gy 0.20% Myelopathy 
Spinal cord 
(20 cm) (10 cm) (5 cm)
– 
(10 
cm) 
(5 cm)
Spinal 
cord 
Max < 50 
Gy 
<5% 
grade >= 
3 toxicity
2 Gy     50.5 617 Lung     60 Gy 6% Myelopathy 4700 5000 5000 7000 7000
Cervical 
spinal 
cord 
EUD < 52 
Gy <5% 
grade >= 
3 toxicity
1.8 Gy 10 cm 50 Gy   436 Esophagus     69 Gy 50% Myelopathy               
Max < 55 
Gy 
1.8 Gy 20 cm 47 Gy   436 Esophagus                                 
3 Gy     36 Gy 937 Lung                                 
4 Gy     30 Gy 937 Lung                                 
Kidney 
1.8 Gy 100% 23 Gy   436 Esophagus 
Kidney, 
bilateral 
Mean <15-18 Gy   <5% 
Clinical 
dysfunction 
Kidney 2300 3000 5000 2800 4000 – Kidney 
Median 
dose < 
17.5 Gy 
Anemia,, 
azotemia, 
HTN, 
edema 
1.8 Gy 67% 30 Gy   436 Esophagus Mean <28 Gy   <50% 
Clinical 
dysfunction 
                    
1.8 Gy 33% 50 Gy   436 Esophagus V12 <55%   <5% 
Clinical 
dysfunction 
                    
2 Gy 50% 14 Gy   630 Sarcoma V20 <32%   <5% 
Clinical 
dysfunction 
                    
3 Gy V18 < 25%   937 Lung V23 <30%   <5% 
Clinical 
dysfunction 
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RTOG data QUANTEC data Emami Data Milano Data
Critical 
Structure 
Dose/ 
fx 
Vol. Dose 
Max. 
Dose 
Protocol Treated organ 
Critical 
Structure 
Vol. Dose/Vol.
Max. 
Dose 
Toxicity 
Rate 
Toxicity 
Endpoint 
Organ TD 5/5     TD 50/5     Organ 
Dose 
tolerance
Endpoint
Liver 
1.8 Gy 50% 35 Gy   436 Esophagus 
Liver 
Mean <30-32 Gy   <5% 
RILD (in 
normal liver 
function) 
Liver 3000 3500 5000 4000 4500 5500
Liver 
1/3: 40-80 
Gy 
Late 
grade 3-4 
liver 
toxicity < 
5% 
3 Gy >700 cc <18 Gy   937 Lung Mean <42 Gy   <50% 
RILD (in 
normal liver 
function) 
              
2/3: 30-50 
Gy 
              Mean <28 Gy   <5% 
RILD (in 
Child-Pugh A 
or HCC) 
              
3/3: 25-
35% 
              Mean <36 Gy   <50% 
RILD (in 
Child-Pugh A 
or HCC) 
                    
Table 3. Radiation tolerance dose in abdomen
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RTOG data Handbook QUANTEC data Emami Data Milano Data
Critical 
Structure 
Dose/fx Vol. Dose 
Max. 
Dose 
Protocol 
Treated 
organ 
Organ 
Partial 
Organ 
Tolerance 
(1.8 – 2.0 
Gy/fx) 
Critical 
Structure
Vol. 
Dose/
Vol. 
Max. 
Dose 
Toxicity 
Rate 
Toxicity 
Endpoint 
Organ TD 5/5     TD 50/5     Organ
Dose 
tolerance
End 
point
Bladder 
1.8 Gy 60% 50 Gy   621 Prostate 
Bladder 
Whole 
50 Gy 
(5-10% 
late) 
Bladder 
(bladder 
cancer) 
    
<65 <6% 
Grade 3+ 
toxicity 
  Whole  2/3  1/3 Whole  2/3  1/3       
1.8 Gy 60% 40 Gy   534 
Postop 
prostate 
Whole 
60 Gy 
(10-40% 
late) 
Bladder 
(prostate 
cancer) 
V65 <50% 
    
Grade 3+ 
toxicity 
Bladder 6500 8000 N/A 8000 8500 N/A       
1.8 Gy 55% 50 Gy   
PMID 
18947938 
RTOG 
Prostate 
Group 
Consensus 
2009 
 1/3 
60 Gy (5-
10% late)
V70 <35% 
    
Grade 3+ 
toxicity 
                    
1.8 Gy 50% 35 Gy   529 Anus  1/3 
70 Gy 
(20% late)
V75 <25% 
    Grade 3+ 
toxicity 
                    
1.8 Gy 50% 65 Gy   415 Prostate 
GYN 
HDR 
<70% 
Point A 
V80 <15% 
    Grade 3+ 
toxicity 
                    
1.8 Gy 40% 40 Gy   822 Rectum Urethra   60-70 Gy                                 
1.8 Gy 40% 65 Gy   534 
Postop 
prostate 
Testis 
Transient 
azosperim
a 
0.5 Gy                                 
1.8 Gy 40% 66.6 Gy   621 Prostate 
Total 
azospermi
a 
0.8-1 Gy                                 
1.8 Gy 35% 40 Gy   529 Anus 
Sterilizati
on 
2-3 Gy                                 
1.8 Gy 35% 45 Gy   418 Endometrial 
Ovary 
Sterilizati
on 
2-3 Gy                                 
1.8 Gy 35% 70 Gy   415 Prostate 
Ovarian 
failure 
5-10 Gy                                 
1.8 Gy 30% 70 Gy   
PMID 
18947938 
RTOG 
Prostate 
Group 
Consensus 
2009 
Vagina 
Upper 
mucosa 
120 Gy                                 
1.8 Gy 25% 75 Gy   415 Prostate 
Mid 
mucosa 
80-90 Gy                                 
1.8 Gy 15% 45 Gy   822 Rectum 
Lower 
mucosa 
60-70 Gy                                 
1.8 Gy 15% 80 Gy   415 Prostate 
Fibrosis/st
enosis 
>50-60 Gy                                 
1.8 Gy 5% 50 Gy   529 Anus Ureter   <75 Gy                                 
1.8 Gy     50 Gy 822 Rectum                                       
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RTOG data Handbook QUANTEC data Emami Data Milano Data
Critical 
Structure 
Dose/fx Vol. Dose 
Max. 
Dose 
Protocol 
Treated 
organ 
Organ 
Partial 
Organ 
Tolerance 
(1.8 – 2.0 
Gy/fx) 
Critical 
Structure
Vol. 
Dose/
Vol. 
Max. 
Dose 
Toxicity 
Rate 
Toxicity 
Endpoint 
Organ 
TD 
5/5 
    TD 50/5     Organ
Dose 
tolerance
End
point
External 
genitalia 
1.8 Gy 50% 20 Gy   529 Anus                                       
1.8 Gy 35% 30 Gy   529 Anus                                       
1.8 Gy 5% 40 Gy   529 Anus                                       
Femoral 
Head 
1.8 Gy 50% 30 Gy   529 Anus 
Femoral 
head 
Adult 42-50 Gy                                 
1.8 Gy 15% 30 Gy   418 
Endometr
ial 
Slipped 
epiphysis
<25 Gy                                 
1.8 Gy 40% 40 Gy   822 Rectum 
Avascular 
necrosis 
30-40 Gy                                 
1.8 Gy 35% 40 Gy   529 Anus                                       
1.8 Gy 25% 45 Gy   822 Rectum                                       
1.8 Gy 10% 50 Gy   534 
Postop 
prostate 
                                      
1.8 Gy 5% 44 Gy   529 Anus                                       
1.8 Gy 5% 50 Gy   
PMID 
18947938 
RTOG 
Prostate 
Group 
Consensu
s 2009 
                                      
2 Gy 5% 60 Gy   630 Sarcoma                                       
1.8 Gy     50 Gy 822 Rectum                                       
1.8 Gy     45 Gy 712 Bladder                                       
Iliac 
crests 
1.8 Gy 50% 30 Gy   529 Anus                                       
1.8 Gy 35% 40 Gy   529 Anus                                       
1.8 Gy 5% 50 Gy   529 Anus                                       
Large 
Bowel 
1.8 Gy 50% 35 Gy   529 Anus                   Colon 
4500 – 5500 5500 – 6500
      
1.8 Gy 35% 40 Gy   529 Anus       
Penile 
bulb 
Mean 
dose to 
95% 
gland 
<50 Gy
  
<35% 
Severe 
erectile 
dysfunction 
obstruction,
perforation,
ulceration 
      
1.8 Gy 5% 50 Gy   529 Anus       D90 <50 Gy
  
<35% 
Severe 
erectile 
dysfunction 
                    
Penile 
Bulb 
1.8 Gy Mean 52.5 Gy   415 Prostate       D60-70 <70 Gy
  
<55% 
Severe 
erectile 
dysfunction 
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RTOG data Handbook QUANTEC data Emami Data Milano Data
Critical 
Structure 
Dose/fx Vol. Dose 
Max. 
Dose 
Protocol 
Treated 
organ 
Organ 
Partial 
Organ 
Tolerance 
(1.8 – 2.0 
Gy/fx) 
Critical 
Structure
Vol. 
Dose/
Vol. 
Max. 
Dose 
Toxicity 
Rate 
Toxicity 
Endpoint 
Organ TD 5/5     TD 50/5     Organ
Dose 
tolerance
End 
point
Rectum 
1.8 Gy 60% 30 Gy   418 Endometrial 
Rectum 
Whole 60 Gy 
Rectum 
V50 <50% 
  
<10% 
Grade 3+ 
toxicity 
Rectum 
6000 – – 8000 – – Rectum
V70-80 <= 
15 cc 
Late 
grade 
2 in < 
5-10%
1.8-2 Gy 50% 55 Gy   712 Bladder 
GYN 
HDR 
<70% 
Point A 
V60 <35% 
  
<10% 
Grade 3+ 
toxicity 
severe 
proctitis, 
necrosis, 
fistula, 
stenosis 
V70 <= 
20-25% 
1.8 Gy 50% 50 Gy   
0621, PM
ID 
18947938 
Prostate       V65 <25% 
  
<10% 
Grade 3+ 
toxicity 
                    
1.8 Gy 50% 60 Gy   415 Prostate       V70 <20% 
  
<10% 
Grade 3+ 
toxicity 
                    
1.8 Gy 35% 65 Gy   415 Prostate       V75 <15% 
  
<10% 
Grade 3+ 
toxicity 
                    
1.8 Gy 25% 66.6 Gy   621 Prostate                                       
1.8 Gy 25% 70 Gy   415 Prostate                                       
1.8 Gy 15% 75 Gy   415 Prostate                                       
1.8 Gy 45% 40 Gy   534 
Postop 
prostate 
                                      
1.8 Gy 25% 65 Gy   534 
Postop 
prostate 
                                      
1.8 Gy 20% 70 Gy   
PMID 
18947938 
RTOG 
Prostate 
Group 
Consensus 
2009 
                                      
 
Physical and Radiobiological Evaluation of Radiotherapy Treatment Plan
http://dx.doi.org/10.5772/60846
131
RTOG data Handbook QUANTEC data Emami Data Milano Data
Critical 
Structure 
Dose/fx Vol. Dose 
Max. 
Dose 
Protocol 
Treated 
organ 
Organ 
Partial 
Organ 
Tolerance 
(1.8 – 2.0 
Gy/fx) 
Critical 
Structure 
Vol.
Dose/
Vol. 
Max. 
Dose 
Toxicity 
Rate 
Toxicity 
Endpoint 
Organ TD 5/5     
TD 
50/5 
    Organ
Dose 
tolerance
End 
point
Small 
Bowel 
1.8 Gy 200 cc 30 Gy   529 Anus 
Small 
bowel 
Small 
volume
50 Gy 
Small 
bowel 
(individual 
loops) 
V15 <120 cc
  
<10% 
Grade 3+ 
toxicity 
Small 
intestine 
4000 – 5000 5500 – 6000
      
1.8 Gy 150 cc 35 Gy   529 Anus Whole <40 Gy 
Small 
bowel 
(peritoneal 
cavity) 
V45 <195 cc
  
<10% 
Grade 3+ 
toxicity 
obstruction,
perforation 
      
1.8 Gy 180 cc 35 Gy   822 Rectum                                       
1.8 Gy 100 cc 40 Gy   822 Rectum                                       
1.8 Gy 20 cc 45 Gy   529 Anus                                       
1.8 Gy 65 cc 45 Gy   822 Rectum                                       
1.8 Gy     50 Gy 
0822, 052
9 
Rectum, 
anus 
                                      
1.8 Gy     52 Gy 
PMID 
18947938 
RTOG 
Prostate 
Group 
Consensus 
2009 
                                      
1.8 Gy 30% 40 Gy   418 Endometrial                                       
Skin, 
longitudi
nal 
2 Gy 50% 20 Gy   630 Sarcoma                                       
Testis 2 Gy 50% 3 Gy   630 Sarcoma Extremity 
Circumfe
rential 
20-30 Gy                                 
Vulva 2 Gy 50% 30 Gy   630 Sarcoma Bone 
marrow 
Whole 
abdomen
<30 Gy                                 
Anus 2 Gy 50% 30 Gy   630 Sarcoma Ablation >40 Gy                                 
Bone, 
weight-
bearing 
2 Gy 50% 50 Gy   630 Sarcoma Bone Cortex 50 Gy                                 
Joints 2 Gy 50% 50 Gy   630 Sarcoma 
Joint 
space 
Fibrotic 
constricti
on 
40-45 Gy                                 
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Table 5. Summary of RTOG acute toxicity criteria for head and neck region.  
Tissue Grade 0 Grade 1 Grade 2 Grade 3 Grade 4 
Skin 
No 
change 
over 
baseline 
Follicular, faint, or dull erythema/epilation/dry 
desquamation/decreased sweating 
Tender or bright erythema, patchy 
moist desquamation/moderate edema 
Confluent, moist desquamation other 
than skin folds, pitting edema 
Ulceration, hemorrhage, 
necrosis 
Mucosal 
membrane 
No 
change 
over 
baseline 
Injection/may experience mild pain not 
requiring analgesic 
Patchy mucositis which may produce 
an inflammatory serosanguinitis 
discharge/may experience moderate 
pain requiring analgesia 
Confluent fibrinous mucositis/may 
include severe pain requiring narcotic 
Ulceration, hemorrhage, or 
necrosis 
Eye 
No 
change 
Mild conjunctivitis with or without scleral 
injection/increased tearing 
Moderate conjunctivitis with or 
without keratitis requiring steroids 
and/or antibiotics/dry eye requiring 
artificial tears/iritis with photophobia 
Severe keratitis with corneal 
ulceration/objective decrease in visual 
acuity or in visual fields/acute 
glaucoma/panophthalmitis 
Loss of vision (unilateral or 
bilateral) 
Ear 
No 
change 
over 
baseline 
Mild external otitis with erythema, pruritus, 
secondary to dry desquamation not requiring 
medication. Audiogram unchanged from 
baseline 
Moderate external otitis requiring 
topical medication/serious otitis 
medius/hypoacusis on testing only 
Severe external otitis with discharge or 
moist desquamation/symptomatic 
hypoacusis/tinnitus, not drug related 
Deafness 
Salivary 
gland 
No 
change 
over 
baseline 
Mild mouth dryness/slightly thickened 
saliva/may have slightly altered taste such as 
metallic taste/these changes not reflected in 
alteration in baseline feeding behavior, such as 
increased use of liquids with meals 
Moderate to complete dryness/thick, 
sticky saliva/markedly altered taste 
 Acute salivary gland necrosis 
Pharynx 
and 
esophagus 
No 
change 
over 
baseline 
Mild dysphagia or odynophagia/may require 
topical anesthetic or non-narcotic 
analgesics/may require soft diet 
Moderate dysphagia or 
odynophagia/may require narcotic 
analgesics/may require puree or liquid 
diet 
Severe dysphagia or odynophagia with 
dehydration or weight loss (>15% from 
pre-treatment baseline) requiring N-G 
feeding tube, I.V. fluids, or 
hyperalimentation 
Complete obstruction, 
ulceration, perforation, fistula
Larynx 
No 
change 
over 
baseline 
Mild or intermittent hoarseness/cough not 
requiring antitussive/erythema of mucosa 
Persistent hoarseness but able to 
vocalize/referred ear pain, sore throat, 
patchy fibrinous exudate or mild 
arytenoid edema not requiring 
narcotic/cough requiring antitussive 
Whispered speech, throat pain, or referred 
ear pain requiring narcotic/confluent 
fibrinous exudate, marked arytenoid 
edema 
Marked dyspnea, stridor, or 
hemoptysis with 
tracheostomy or intubation 
necessary 
CNS 
No 
change 
Fully functional status (i.e., able to work) with 
minor neurologic findings, no medication 
needed 
Neurologic findings present sufficient 
to require home case/nursing 
assistance may be 
required/medications including 
steroids/anti-seizure agents may be 
required 
Neurologic findings requiring 
hospitalization for initial management 
Serious neurologic 
impairment which includes 
paralysis, coma, or seizures >3 
per week despite 
medication/hospitalization 
required 
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 Organ/Tissue Grade 0 Grade 1 Grade 2 Grade 3 Grade 4
Upper G.I No change 
Anorexia with <=5% weight loss 
from pretreatment baseline/nausea 
not requiring antiemetics/abdominal 
discomfort not requiring 
parasympatholytic drugs or 
analgesics 
Anorexia with <=15% weight loss 
from pretreatment baseline/nausea 
and/or vomiting requiring 
antiemetics/abdominal pain 
requiring analgesics 
Anorexia with >15% weight loss from 
pretreatment baseline or requiring N-G tube or 
parenteral support. Nausea and/or vomiting 
requiring tube or parenteral support/abdominal 
pain, severe despite medication/hematemesis or 
melena/abdominal distention (flat plate 
radiograph demonstrates distended bowel 
loops) 
Ileus, subacute or acute obstruction, 
performation, GI bleeding requiring 
transfusion/abdominal pain requiring 
tube decompression or bowel 
diversion 
Lower G.I No change 
Increased frequency or change in 
quality of bowel habits not requiring 
medication/rectal discomfort not 
requiring analgesics 
Diarrhea requiring 
parasympatholytic drugs (e.g., 
Lomotil)/mucous discharge not 
necessitating sanitary pads/rectal 
or abdominal pain requiring 
analgesics 
Diarrhea requiring parenteral support/severe 
mucous or blood discharge necessitating 
sanitary pads/abdominal distention (flat plate 
radiograph demonstrates distended bowel 
loops) 
Acute or subacute obstruction, fistula 
or perforation; GI bleeding requiring 
transfusion; abdominal pain or 
tenesmus requiring tube 
decompression or bowel diversion 
Lung No change 
Mild symptoms of dry cough or 
dyspnea on exertion 
Persistent cough requiring 
narcotic, antitussive 
agents/dyspnea with minimal 
effort but not at rest 
Severe cough unresponsive to narcotic 
antitussive agent or dyspnea at rest/clinical or 
radiologic evidence of acute 
pneumonitis/intermittent oxygen or steroids 
may be required 
Severe respiratory 
insufficiency/continuous oxygen or 
assisted ventilation 
Genitourinary No change 
Frequency of urination or nocturia 
twice pretreatment habit/dysuria, 
urgency not requiring medication 
Frequency of urination or nocturia 
that is less frequent than every 
hour. Dysuria, urgency, bladder 
spasm requiring local anesthetic 
(e.g., Pyridium) 
Frequency with urgency and nocturia hourly or 
more frequently/dysuria, pelvis pain, or bladder 
spasm requiring regular, frequent narcotic/gross 
hematuria with/without clot passage 
Hematuria requiring 
transfusion/acute bladder obstruction 
not secondary to clot passage, 
ulceration, or necrosis 
Heart 
No change over 
baseline 
Asymptomatic but objective 
evidence of EKG changes or 
pericardial abnormalities without 
evidence of other heart disease 
Symptomatic with EKG changes 
and radiologic findings of 
congestive heart failure or 
pericardial disease/no specific 
treatment required 
Congestive heart failure, angina pectoris, 
pericardial disease responding to therapy 
Congestive heart failure, angina 
pectoris, pericardial disease, 
arrhythmias not responsive to non-
surgical measures 
 
Table 6. Summary of RTOG acute toxicity criteria for body region.
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 Organ/Tissue Grade 0 Grade 1 Grade 2 Grade 3 Grade 4 Organ/Tissue 
Subcutaneous 
tissue 
None 
Slight atrophy; pigmentation 
change; some hair loss 
Patch atrophy; moderate 
telangiectasia; total hair loss 
Marked atrophy; gross telangiectasia Ulceration 
Death related to radiation 
effects 
Mucosis 
membrane 
None 
slight induration (fibrosis), 
and loss of subcutaneous fat 
Moderate fibrosis but 
asymptomatic; slight field 
contracture; <10% linear 
reduction 
Severe induration and loss of 
subcutaneous tissue; field contracture 
> 10% linear measurement 
Necrosis 
Death related to radiation 
effects 
Mucosis 
membrane 
None Slight atrophy and dryness 
Moderate atrophy and 
telangiectasia; little mucous 
Marked atrophy with complete 
dryness; severe telangiectasia 
Ulceration 
Death related to radiation 
effects 
Salivary 
gland 
None 
Slight dryness of mouth; good 
response on stimulation 
Moderate dryness of mouth; 
poor response on stimulation 
Complete dryness of mouth; no 
response on stimulation 
Fibrosis 
Death related to radiation 
effects 
Spinal cord None Mild L’Hermitte’s syndrome Severe L’Hermitte’s syndrome 
Objective neurological findings at or 
below cord level treated 
Mono, para quadriplegia 
Death related to radiation 
effects 
Brain None 
Mild headache; slight 
lethargy 
Moderate headache; great 
lethargy 
Severe headaches; severe CNS 
dysfunction (partial loss of power or 
dyskinesia) 
Seizures or paralysis; coma
Death related to radiation 
effects 
Eye None 
Asymptomatic cataract; 
minor corneal ulceration or 
keratitis 
Symptomatic cataract; moderate 
corneal ulceration; minor 
retinopathy or glaucoma 
Severe keratitis; severe retinopathy or 
detachment severe glaucoma 
Panophthalmitis/blindness
Death related to radiation 
effects 
Larynx None 
Hoarseness; slight arytenoid 
edema 
Moderate arytenoid edema; 
chondritis 
Severe edema; severe chondritis Necrosis 
Death related to radiation 
effects 
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Organ/Tiss
ue 
Grade 0 Grade 1 Grade 2 Grade 3 Grade 4 Grade 5 
Lung None 
Asymptomatic or mild symptoms (dry 
cough); slight radiographic appearances 
Moderate symptomatic fibrosis or 
pneumonitis (severe cough); low grade 
fever; patchy radiographic appearances 
Severe symptomatic fibrosis or 
pneumonitis; dense radiographic changes 
Severe respiratory 
insufficiency/continuous 
O2/assisted ventilation 
Death related to 
radiation effects 
Heart None 
Asymptomatic or mild symptoms; 
transient T wave inversion and ST 
changes; sinus tachycardia >110  
Moderate angina on effort; mild 
pericarditis; normal heart size; persistent 
abnormal T wave and ST changes; low 
ORS 
Severe angina; pericardial effusion; 
constrictive pericarditis; moderate heart 
failure; cardiac enlargement; EKG 
abnormalities 
Tamponade/severe heart 
failure/severe constrictive 
pericarditis 
Death related to 
radiation effects 
Esophagus None 
Mild fibrosis; slight difficulty in 
swallowing solids; no pain on 
swallowing 
Unable to take solid food normally; 
swallowing semi-solid food; dilation 
may be indicated 
Severe fibrosis; able to swallow only 
liquids; may have pain on swallowing; 
dilation required 
Necrosis/perforation fistula 
Death related to 
radiation effects 
Small/large 
intestine 
None 
Mild diarrhea; mild cramping; bowel 
movement 5 times daily; slight rectal 
discharge or bleeding 
Moderate diarrhea and colic; bowel 
movement >5 times daily; excessive rectal 
mucus or intermittent bleeding 
Obstruction or bleeding, requiring surgery Necrosis/perforation fistula 
Death related to 
radiation effects 
Liver None 
Mild lassitude; nausea, dyspepsia; 
slightly abnormal liver function 
Moderate symptoms; some abnormal 
liver function tests; serum albumin 
normal 
Disabling epatitis insufficiency; liver 
function tests grossly abnormal; low 
albumin; edema or ascites 
Necrosis/hepatic coma or 
encephalopathy 
Death related to 
radiation effects 
Kidney None 
Transient albuminuria; no 
hypertension; mild impairment of renal 
function; urea 25–35 mg%; creatinine 
1.5–2.0 mg%; Creatinine clearance > 
75% 
Persistent moderate albuminuria (2+); 
mild hypertension; no related anemia; 
moderate impairment of renal function; 
urea > 36–60mg%; creatinine clearance 
(50–74%) 
Severe albuminuria; severe hypertension 
persistent anemia (< 10%); severe renal 
failure; urea > 60 mg%; creatinine > 4.0 
mg%; creatinine clearance < 50% 
Malignant hypotension; 
uremic coma/urea > 100% 
Death related to 
radiation effects 
Bladder None 
Slight epithelial atrophy; minor 
telangiectasia (microscopic hematuria) 
Moderate frequency; generalized 
telangiectasia; intermittent macroscopic 
hematuria 
Severe frequency and dysuria; severe 
generalized telangiectasia (often with 
petechiae); frequent hematuria; reduction 
in bladder capacity (< 150 cc) 
Necrosis/contracted bladder 
(capacity < 100 cc); severe 
hemorrhagic cystitis 
Death related to 
radiation effects 
Bone None 
Asymptomatic; no growth retardation; 
reduced bone density 
Moderate pain or tenderness; growth 
retardation; irregular bone sclerosis 
Severe pain or tenderness; complete arrest 
of bone growth; dense bone sclerosis 
Necrosis/spontaneous 
fracture 
Death related to 
radiation effects 
Joint None 
Mild joint stiffness; slight limitation of 
movement 
moderate stiffness; intermittent or 
moderate joint pain; moderate limitation 
of movement 
Severe joint stiffness; pain with severe 
limitation of movement 
Necrosis/complete fixation 
Death related to 
radiation effects 
 
Table 8. Summary of RTOG late toxicity criteria by body region.
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6. Radiation treatment plan analysis programs
In modern radiation therapy, physical dose indices, such as mean doses, dose-volume
histograms (DVHs), and isodose distribution charts, are often used for treatment plan
evaluation. DVHs provide dose volume coverage information. However, they fail to provide
information regarding hot spots and dose homogeneity. When reviewing physical dose
indices, the resulting biological objectives, such as tumor control rate and normal tissue
complication probability, must be indirectly estimated based on clinical experience and
knowledge. In some competing plans, it is possible that a similar mean dose, maximum dose,
or minimum dose might have significantly different radiobiological outcomes. To facilitate the
direct and accurate comparison and ranking of treatment plans, radiobiological models for
treatment plan evaluation have been introduced. These radiobiological models are based on
the idea that the radio-sensitivity of different organs should be taken into account. As a result,
the physical dose delivered to an organ is directly associated with the dose–response proba‐
bility of inducing complications in normal tissues. Many programs have been designed and
developed to calculate both dosimetrical and biological indices, as shown in Table 9 [10-29].
7. Multidisciplinary strategies: Planning decision support concept
7.1. Methods could be used for planning a decision support system
In this section, we highlight dosimetrical and biological models in radiation oncology treat‐
ment planning, with focus on the methodological aspects of prediction model development.
In radiation treatment planning analysis, dose volume histograms were the most widely used
quantitative results. To comprehensively evaluate a certain DVH, we proposed several
dosimetrical and biological models in the earlier sections. For dosimetrical models, there were
PTTV, CI, and TCI for target coverage index, and MHI, HI for homogeneity index and COSI,
QF, and CQI for overall index. For radiobiological models, there were TCP and NTCP for tumor
or critical structures, representatively. There were still other factors like treatment time,
planning time, or overall moniter unites irradiated in patients could be helpful for making
more reasonable decision. Some characteristic prognostic and predictive factors like radiation-
induced organ toxicities were discussed in earlier sections. We also enumerate the normal
tissue tolerance criteria including QUENTEC and EMAMI database.
7.2. The need of plan decision support concept in RT
With the emergence of individualized medicine and the increasing amount and complexity of
available medical data, a growing need exists for the development of planning decision-
support systems based on prediction models of treatment outcome [55-57]. In radiation
oncology, these models combine both predictive and prognostic data factors from dosimetri‐
cal, biological, imaging, and other sources to achieve the highest accuracy to predict tumor
response and follow-up event rates. The central challenge, however, is how to integrate
diverse, multimodal information (imaging, dosimetrical, biological, and other data) in a
quantitative manner to provide specific clinical predictions that accurately and robustly
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estimate patient outcomes as a function of the possible decisions. Currently, many prediction
models are being published that consider factors related to disease and treatment, but without
standardized assessments of their robustness, reproducibility, or clinical utility [58]. Conse‐
quently, these prediction models might not be suitable for clinical decision-support systems
for routine care.
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Patient 
information 
Data 
format 
Data 
compatibility 
Compatible 
with PACS 
3D image 
module 
Physical Biological 
Overall 
Multi-
RTP 
Analysis 
database 
Statistical analysis 
Independence 
from GUI 
Platform Author Paper Year Others 
DVH 
calculator 
Physical 
index 
TCP/NTCP
Normal 
statistic
Survival 
statistic 
HART × 
AAPM/
RTOG, 
DicomR
T 
Pinnacle × √ √ √ √ × × × × × × MatLab Anil 
Pyakuryal
(23) 2010 
http://www2.ui
c.edu/~apyaku1
/ 
CERR × 
AAPM/
RTOG, 
DicomR
T 
(toolbox) 
Pinnacle, 
expand 
function 
with 
DicomRT 
toolbox 
× √ √ × × × × √ × × √ 
MatLab, 
Fortran, 
C/C++, Java
Joseph O. 
Deasy 
(10) 2003 
http://www.cerr
.info/about.php
DREES √ 
Matlab’s 
human-
readable 
data 
structure
s 
No × × × × √ × × × × √ × MatLab Joseph O. 
Deasy 
(11) 2006 
http://cerr.info/
drees/about.php
EUD-based 
mathematical 
model 
× DVH file 
specialized 
format 
× × × × √ × × × × × × MatLab Andrzej 
Niemierko
(12) 2007   
EUCLID √ 
AAPM/
RTOG, 
DicomR
T 
LANTIS 
and IMPAC 
based on 
DRESS 
× × × × √ × × × × √ × MatLab Olivier 
Gayou 
(13) 2007   
Dose Volume 
Histogram 
Analyzer 
× 
Eclipse, 
Pinnacle, 
Tomo, 
DVH 
files 
Eclipse, 
Pinnacle, 
Tomo 
× × × × √ × × × × × × MatLab Jin Sung 
Kim 
(17) 2008 
http://mpjinsun
g.tistory.com/en
try/DVH-
Analyzer-v10 	
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database 
Statistical analysis 
Independence 
from GUI 
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DVH 
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TCP/NTCP
Normal 
statistic
Survival 
statistic 
computational 
platform 
√ 
AAPM/
RTOG, 
DicomR
T 
compatible 
with ARIA, 
different 
RTP 
√ √ × × √ × × √ × √ √ MatLab, 
Web, ARIA
Dezhi Liu (18) 2009   
BIOPLAN × DVH file DVH file × × × × √ × × × × × × Microsoft 
Visual Basic
B. 
SANCHEZ
-NIETO 
(52) 2000   
Anonymous × DVH file DVH file × × × × √ × × × × × × MatLab Arun S. 
Oinam 
(21) 2011   
SlicerRT √ Dicom 
RT 
compatible 
with 
cormercial 
RTP 
× √ × × √ × × × × × √ C++ Csaba 
Pinter 
(22) 2012 
https://www.ass
embla.com/spac
es/slicerrt/wiki 
MERT √ Dicom 
RT  
This was 
RTP 
× √ √ × √ × × × × × √ Multi 
format(MC)
Murat 
Surucu 
(26) 2010   
DIRART × 
Dicom 
RT 
use CERR 
import 
engine 
× √ × × √ × × × × × √ MatLab Deshan 
Yang 
(27) 2010 
http://code.goo
gle.com/p/dirart
/ 
SABER × 
Dicom 
RT 
Eclipse  × × × × √ × × × × × × MatLab Jay 
Burmeister
(29) 2010   
DICOM RT 
toolbox 
√ Dicom 
RT 
Helax TMS × √ √ × × × × × × × × MatLab Spezi E (24) 2002   	
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from GUI 
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statistic 
BEUDcal × DVH file DVH file × × √ × √ × × × × × × MatLab Su FC (25) 2010   
Comp Plan × DVH file 
DVH file in 
Excel 
× × × × √ × × × × × × MatLab Holloway 
LC 
(15) 2012   
CalcNTCP × 
Manual 
input 
Manual 
input 
× × × × √ × × × × × × Visual Basic Khan HA (16) 2007   
RADBIOMOD × DVH file 
Manual 
input 
× × × √ √ × × × × × × Microsoft 
Ecel 
Chang JH (53) 2011 
https://sites.goo
gle.com/site/rad
biomod/home 
BioSuite × DVH file 
Pinnacle, 
Eclups 
× × √ × √ × × × × × √ C++ J Uzan (54) 2012   
RTToolbox √ Dicom 
RT 
Virtuos, our 
in-house 
developed 
planning 
system 
× √ √ × √ × × √ × × √ C++ Lanlan, 
Zhang 
(28) 2013   	
Table 9. Review of previous programs
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Decision making in radiotherapy is mainly based on clinical features, such as the patient
performance status, organ function, and grade and extent of the tumor (e.g., as defined by the
TNM system). In almost all studies, such features have been found to be prognostic for survival
and development of toxicity [59, 60]. Consequently, these features should be evaluated in
building robust and clinically acceptable radiotherapy prognostic and predictive models.
Moreover, measurement of some clinical variables, such as performance status, can be
captured with minimal effort.
Toxicity measurements and scoring should also build on validated scoring systems, such as
the Common Terminology Criteria for Adverse Events (CTCAE), which can be scored by the
physician or patient [50, 61]. Indeed, a meta-analysis showed that high-quality toxicity
assessments from observational trials are similar to those of randomized trials. [45, 46]
However, a prospective protocol must clarify which scoring system was used and how changes
in toxicity score were dealt with over time with respect to treatment. Finally, to ensure a
standardized interpretation, the reporting of clinical and toxicity data and their analyses
should be performed in line with the STROBE (Strengthening the Reporting of Observational
Studies in Epidemiology) statement for observational studies and genetic-association studies,
which is represented as checklists of items that should be addressed in reports to facilitate the
critical appraisal and interpretation of these types of studies (Figure 7).
Figure 7. Design of planning decision support concept in radiotherapy treatment planning.
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Despite the challenges that remain, the vision of predictive models leading to plan decision
support concept that are continuously updated via rapid learning on large datasets is clear,
and numerous steps have already been taken. These include universal data-quality assurance
programs and semantic interoperability issues. However, we believe that this truly innovative
journey will lead to necessary improvement of healthcare effectiveness and efficiency. Indeed,
investments are being made in research and innovation for health-informatics systems, with
an emphasis on interoperability and standards for secured data transfer, which shows that
“eHealth” will be among the largest health-care innovations of the coming decade. Accurate,
externally validated prediction models are being rapidly developed, whereby multiple
features related to the patient’s disease are combined into an integrated prediction. The key,
however, is standardization—mainly in data acquisition across all areas, including dosimet‐
rical-based and biological-based models, patient preferences, and possible treatments. These
crucial features are the basis of validating a plan decision support system, which, in turn, will
stimulate developments in rapid-learning health care and will enable the next major advances
in shared decision making.
8. Conclusion
Plan comparison studies still remain controversial. The main reason for this is because plan
parameters, optimization methods, and OAR constraints are difficult to clearly define. Many
researchers have focused on the influence of planning parameters on the results of treatment
plans [62-64]. For instance, Gutiérrez et al. [65] reported that the use of a field width of 1 cm
resulted in dosimetrically superior plans for brain irradiation compared to plans that use a
field width of 2.5 cm. More recently, Skorska and Piotrowski studied the influence of treat‐
ment-planning parameters on plan qualities for prostate cancer patients using helical tomo‐
therapy [66]. This study revealed that using a field width of 1 cm, instead of 5 cm, leads to
decreases in the D20%, D40%, D60%, and D80% of the small intestine by 2.45%, 8.48%, 6.36%,
and 5%. This results in 1.22Gy, 4.24Gy, 3.18Gy, and 2.50Gy, respectively, for the prescribed
dose of 50 Gy. Another bias of plan comparison studies is that the quality of a planner’s abilities
and planning techniques may vary. Performing repeat planning processes and using multiple
planners to cross check would minimize such bias. The use of OAR dose tolerance guidelines,
such as RTOG or QUENTEC protocols, would minimize human error.
Other major issues among plan comparison studies are the method of plan analysis and
evaluation. Many studies have focused on developing a simple index that represents the
overall quality of plans [14, 19, 41, 42, 67]. However, none of these plans are easily used in a
clinic. There is a need for programs that can easily calculate dosimetrical and biological indices
[10, 12, 13, 15, 16, 22-25, 28, 68, 78-82].
There is a growing trend of studying the relationships between treatment plan results and
clinical outcomes, such as toxicities, survival, and patterns of failure [69-77]. Such studies may
help physicians and physicists learn more about the influence of plan results and plan quality
on patient treatment.
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